PGEN — PRECIGEN, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1356090 ·
Last close
$4.29
Market Cap
$1.54B
52W High
$8.98
52W Low
$3.04
ADV30
6,525,046
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 74,148,000 67,640,000 38,650,000 35,766,000 212,102,000 14,959,000 128,308,000
Jun 2026 54,978,000 52,173,000 22,642,000 20,071,000 170,296,000 16,329,000 126,720,000
Mar 2026 23,252,000 20,693,000 -5,994,000 -7,929,000 138,627,000 7,480,000 118,392,000
Dec 2025 4,565,000 2,969,000 -21,666,000 -23,503,000 155,505,000 30,234,000 134,594,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-73,213,000
Investing CF
$73,549,000
Financing CF
$295,000
CapEx
$-1,103,000
Dividends Paid
—
Buybacks
$-537,000
EPS Diluted TTM
$-0.95
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,293,440,000
Inventory
$22,915,000
Receivables
$96,619,000
ST Investments
$31,112,000
EBIT TTM
$36,426,000
Pretax Income TTM
$24,605,000
Interest Exp TTM
$11,821,000
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$156,943,008
EBITDA
$38,080,000
Free Cash Flow
$-87,127,128
Enterprise Value
$1,655,254,400
Total Cash
$46,071,000
Total Debt
$98,607,000
Shares Out
358,549,980
Trailing EPS
$0.11
Book Value
$0.23
ROE
38.8%
ROA
11.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 9,684,000 -106,600,000 -250,642,000 155,505,000 134,594,000 20,911,000 -87,831,000
Dec 2024 3,925,000 -94,705,000 -126,235,000 145,266,000 106,753,000 38,513,000 -68,173,000
Dec 2023 6,225,000 -88,923,000 -95,904,000 151,043,000 32,545,000 118,498,000 -66,930,000
Dec 2022 26,909,000 -74,606,000 28,317,000 215,977,000 89,718,000 126,259,000 -65,045,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
$-157,705,000
OpCashFlow TTM
—
Assets (Latest)
$170,296,000
Forward EPS
$-0.22

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $5.00 · spot: $4.27 · call volume: 371 · put volume: 39
Expected Move to 2026-12-18: ±$0.90 (21.08%) — implied range $3.37 – $5.17 · ATM straddle on $4.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ADRX ADARx Pharmaceuticals, Inc. $1.53B $13.82 —
NRIX Nurix Therapeutics, Inc. $1.56B $14.24 —
SRPT Sarepta Therapeutics, Inc. $1.58B $14.77 —
KLRA Kailera Therapeutics, Inc. $1.58B $12.20 —
ANIP ANI PHARMACEUTICALS INC $1.59B $69.99 —

News headlines (Yahoo Finance, 1h cache)

Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule
2026-11-10 11:30 · Yahoo
What Makes Precigen (PGEN) a New Buy Stock
2026-11-09 16:00 · Yahoo
PGEN Q3 Earnings Call Highlights Launch Momentum and Competition
2026-11-09 14:00 · Yahoo
Precigen (PGEN) Stock Looks Fully Priced On Current Earnings
2026-11-06 17:20 · Yahoo
Precigen (PGEN) Q3 2026 Earnings Call Transcript
2026-11-05 17:20 · Yahoo
Citizens Raises Papzimeos Sales Forecast After Precigen’s Q3 Topline Beat – Sees 142% Upside Potential In PGEN Stock
2026-11-05 11:55 · Yahoo
Precigen Inc (PGEN) Q3 2026 Earnings Call Highlights: Triple-Digit Revenue Surge, First ...
2026-11-05 05:18 · Yahoo
What Precigen (PGEN) Said on Its Q3 Earnings Call
2026-11-05 05:14 · Yahoo
Precigen, Inc. (PGEN) Q3 Earnings and Revenues Miss Estimates
2026-11-04 21:50 · Yahoo
Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance
2026-11-04 21:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.